New study aims to calm inflammation in preterm infants

NCT ID NCT07254000

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for very premature babies (born between 24 and 29 weeks) to find the safest and most effective dose of a medicine called anakinra, which helps reduce inflammation. About 24 infants will receive anakinra through an IV or a shot under the skin. Researchers will measure how the drug moves through the body and check for early signs of lung and brain health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia Inflammation inflammatory disease Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Monash Children's Hospital

    RECRUITING

    Clayton, Victoria, 3168, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Starship Children's Hospital

    NOT_YET_RECRUITING

    Grafton, Auckland, 1023, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact